Advances in Emerging Therapies for Multiple Myeloma
10.3971/j.issn.1000-8578.2023.22.0874
- VernacularTitle:多发性骨髓瘤新型治疗方案的研究进展
- Author:
Chenjing QIAN
1
;
Mei HONG
;
Linghui XIA
Author Information
1. Department of Hematology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China
- Publication Type:Research Article
- Keywords:
Multiple myeloma;
Monoclonal antibodies;
Antibody-drug conjugate;
Bispecific antibodies;
CAR-T
- From:
Cancer Research on Prevention and Treatment
2023;50(3):321-325
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is an incurable plasma cell malignancy with a typical course characterized by response to initial treatment and eventual resistance. Despite major advances in the clinical treatment of multiple myeloma driven by the introduction of new drugs (e.g., proteasome inhibitors and immunomodulators), MM remains incurable. Nevertheless, subsequent cycles of remission and relapse continue as long as new treatments are available to patients. With the development of many new treatments, the approval of 12 new drugs over the past 15 years, and the promising trend of clinical trials, the treatment landscape has dramatically changed and patient survival has improved. This article reviews the progress of new treatments for MM.
